Connect with us
New York-based Atai Life Sciences (Nasdaq: ATAI) reported a net loss of $26.3 million for the third quarter, down year-over-year from its net income of $43.3...
Enveric Biosciences (NASDAQ: ENVB) agreed to license one of its experimental psychedelic drug candidates to MycoMedica Life Sciences in a deal worth as much as $62...
Relmada also told investors that it didn’t think it had enough money to last a year from now. Relmada Therapeutics (Nasdaq: RLMD) provided a corporate update...
Massachusetts voters on Tuesday rejected a ballot measure that would have legalized a selection of naturally-derived psychedelic substances to treat mental health disorders. The measure failed...
Compass Pathways (NASDAQ: CMPS) plans to cut about 30% of its workforce and halt early-stage research programs as the firm focuses resources on completing late-stage trials...
Australian biotech firm Tryptamine Therapeutics Limited (ASX: TYP) secured A$6 million in new funding through a strategic placement. The placement, priced at A$0.02 per share, was...
Shares of Alto Neuroscience Inc. (NYSE: ANRO) collapsed Wednesday after the company’s experimental depression treatment failed in a six-week clinical trial. The Mountain View, California-based company...
MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) said its experimental ketamine-based drug outperformed currently available pain treatments in preclinical studies, building on months of research that show why...
Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped more than 100% in early-morning trading Friday after the psychedelic drug developer announced a $35 million private placement,...
The Open:Minds Expo will focus on introducing consumers to psychedelic therapy and offer training programs for practitioners. As Colorado works to finalize rules around its soon-to-come...
